Effect of paracetamol in gastrointestinal cancer surgery

Phase 2

• Conditions: Condition 1: Gastrointestinal Malignancies. Condition 2: Gastrointestinal Malignancies. Condition 3: Gastrointestinal Malignancies. Condition 4: Gastrointestinal Malignancies.; Malignant neoplasm of stomach; Malignant neoplasm of colon; Malignant neoplasm of oesophagus; Malignant neoplasm of small intestine

• Registration Number: IRCT201207283305N4
• Lead Sponsor: Vice-chancellor of Research Babol University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

ASA class I-III; patient whom candidates GI Malignancy surgery and are hospitalized in ICU ward after surgery.
Exclusion criteria: A History of sensitivity to paracetamol; kidney disease (end stage); liver disease or more than two times increase in the liver enzymes; severe malnutrition or dehydration; alcohol users; Recipients Recipients probensid, Salyslamyd or drugs that are induce liver enzymes.Severe drop in blood pressure during or after, severe dyspnea requiring respiratory support, severe thrombocytopenia, decreased level of consciousness.

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Reduce pain. Timepoint: Three days after surgery. Method of measurement: VAS.

Secondary Outcome Measures

Name	Time	Method
ausea & Vomiting. Timepoint: Three days after surgery. Method of measurement: Visual and questional.